ArticleMedical oncology (Northwood, London, England)2016
Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma.
Article in Medical oncology (Northwood, London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies.Current oncology reports · 2023Pooled it
- Complementary therapies in early breast cancer: Oncologists' evidence-based decisions in a Southeast European vignette survey.Biomolecules & biomedicine · 2025Article
- Education of non-medical practitioners in Germany-an analysis of course subjects of specialized schools.Wiener medizinische Wochenschrift (1946) · 2024Article
- Introducing a standardized assessment of patients' interest in and usage of CAM in routine cancer care: chances and risks from patients' and physicians' point of view.Journal of cancer research and clinical oncology · 2023Article
- Self-efficacy in relation to the use of complementary and alternative medicine, lifestyle choices and cancer aetiology.Journal of cancer research and clinical oncology · 2022Article
- Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment.Journal of cancer research and clinical oncology · 2022Article
- Complementary Medicine in the Treatment of Cancer Patients.Deutsches Arzteblatt international · 2021Article
- The trends of complementary alternative medicine use among cancer patients.BMC complementary medicine and therapies · 2021Article
- Physician Attitudes and Perceptions of Complementary and Alternative Medicine (CAM): A Multicentre Italian Study.Frontiers in oncology · 2020Article
- Herb-drug interactions: a novel algorithm-assisted information system for pharmacokinetic drug interactions with herbal supplements in cancer treatment.European journal of clinical pharmacology · 2019Article
- Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies.Melanoma management · 2018Review
- The use of complementary and alternative medicine by patients in routine care and the risk of interactions.Journal of cancer research and clinical oncology · 2018Article
- Economic Evaluation of Complementary and Alternative Medicine in Oncology: Is There a Difference Compared to Conventional Medicine?Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2017Review
- Use of complementary and alternative medicine by patients with cancer: a cross-sectional study at different points of cancer care.Medical oncology (Northwood, London, England) · 2016Article
- Cancer Patient Motives and Expectations on Non-medical Practitioners.In vivo (Athens, Greece)Article
- Counseling on Complementary Methods in the Treatment of Side Effects of Oncological Therapies: A Project of the Breast and Bowel Center Nahe at the Hospital Sankt Marienwoerth Bad Kreuznach.Integrative cancer therapiesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complementary and alternative medicine (CAM) is used widely among cancer patients. Beside the risk of interaction with cancer therapies, interactions with treatment for comorbidities are an underestimated problem. The aim of this study was to assess prevalence of interactions between CAM and drugs for comorbidities from a large CAM usage survey on melanoma patients and to classify herb-drug interactions with regard to their potential to harm. Consecutive melanoma outpatients of seven skin cancer centers were asked to complete a standardized CAM questionnaire including questions to their CAM use and their taken medication for comorbidities and cancer. Each combination of conventional drugs and complementary substances was evaluated for their potential of interaction. 1089 questionnaires were eligible for evaluation. From these, 61.6% of patients reported taking drugs regularly from which 34.4% used biological-based CAM methods. Risk evaluation for interaction was possible for 180 CAM users who listed the names or substances they took for comorbidities. From those patients, we found 37.2% at risk of interaction of their co-consumption of conventional and complementary drugs. Almost all patients using Chinese herbs were at risk (88.6%). With a high rate of CAM usage at risk of interactions between CAM drugs and drugs taken for comorbidities, implementation of a regular assessment of CAM usage and drugs for comorbidities is mandatory in cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.